MedTrace Logo

Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG

NCT01978015 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2013-11-07

No results posted yet for this study

Summary

Glaucoma, a progressive optic disc neuropathy causing visual field reduction, is the second leading cause of world blindness. The treatment of glaucoma is mainly based in reducing intraocular pressure (IOP) with topical medications. Many patients required two or more medications to achieve a target IOP. Combinations of B-blockers and prostaglandin analogs (PGA) are frequently used in clinical practice because their additive effect in lowering IOP levels. The aim of this study was to investigate the effects of fixed combinations of timolol maleate and PGA on the blood-aqueous barrier and evaluate the measurement of foveal thickness in pseudophakic patients with primary open-angle glaucoma (POAG).

Conditions

  • Uveitis, Anterior
  • Cystoid Macular Edema

Interventions

DRUG

travoprost and timolol maleate fixed combination

travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months

DRUG

latanoprost and maleate timolol fixed combination

Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months

DRUG

bimatoprost and timolol maleate fixed combination

bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months

DRUG

dextran and hypromellose

Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months

Sponsors & Collaborators

  • University of Campinas, Brazil

    lead OTHER

Principal Investigators

  • Alana M Santana, MD · University of Campinas, Brazil

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-07-31
Completion
2013-01-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01978015 on ClinicalTrials.gov